Antengene Announces First Patient Dosed of Small Molecule ATR ATG-018 for the Treatment of Patients with Advanced Solid Tumors and Hematologic Malignancies in Australia
ATG-018, a global rights asset developed by Antengene's internal R&D team, is an orally-bioavailable, small molecule ataxia telangiectasia and Rad3-associated (ATR) kinase inhibitor that targets the DNA damage response (DDR) pathways. The Phase I study will evaluate the safety, pharmacology and preliminary efficacy of ATG-018 monotherapy in patients with advanced tumors and hematologic malignancies. SHANGHAI and HONG KONG, Aug. 16, 2022 /PRNewswire/ --Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical com...
Source: singaporestar.com